about
Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARgamma agonists.Effect of oxime ether incorporation in acyl indole derivatives on PPAR subtype selectivity.Synthesis and Biological Evaluation of N-[2-(4-Hydroxyphenylamino)-pyridin-3-yl]-4-methoxy-benzenesulfonamide (ABT-751) Tricyclic Analogues as Antimitotic and Antivascular Agents with Potent in Vivo Antitumor Activity.Synthesis, biological evaluation and docking studies of 4-amino-tetrahydroquinazolino[3,2-e]purine derivatives.Novel benzopyridothiadiazepines as potential active antitumor agents.Docking study of ligands into the colchicine binding site of tubulin.Antioxidant activity of benzoxazolinonic and benzothiazolinonic derivatives in the LDL oxidation model.S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.Lipid-lowering properties of 6-benzoyl-2(3H)-benzothiazolone and structurally related compounds.Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.In vitro pharmacokinetic profile of a benzopyridooxathiazepine derivative using rat microsomes and hepatocytes: identification of phases I and II metabolites.Synthesis of triazoloquinazolinone based compounds as tubulin polymerization inhibitors and vascular disrupting agents.Structural elucidation of degradation products of a benzopyridooxathiazepine under stress conditions using electrospray orbitrap mass spectrometry - study of degradation kinetic.Stereoselective synthesis of enantiopure N-protected-3-arylpiperazines from keto-estersAntioxydant activity of β-carboline derivatives in the LDL oxidation modelScavenging of reactive oxygen species by letosteine, a molecule with two blocked-SH groups. Comparison with free-SH drugsPharmacokinetic evaluation of a novel benzopyridooxathiazepine derivative as a potential anticancer agentEGF-Containing Membrane-Bound Mucins: A Hidden ErbB2 Targeting Pathway?MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale ThermophoresisPublisher Correction: MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale ThermophoresisEffect of 6-Benzoyl-benzothiazol-2-one scaffold on the pharmacological profile of α-alkoxyphenylpropionic acid derived PPAR agonistsSynthesis of a novel series of (Z)-3,5-disubstituted thiazolidine-2,4-diones as promising anti-breast cancer agents
P50
Q37977108-2B176F56-6625-498A-A9DF-768AFA0559FCQ38310949-FA9A8F31-1BF7-42DC-BC56-D77C7D16ED18Q38320967-112A4B1F-2FE4-45B3-89DC-CF021A168DA6Q38751222-B38FE8FE-4783-46F8-A012-C9D29F5B88B8Q39649496-C3459EBF-0AC2-43FE-A3D6-B215280AA253Q40352749-B93D6D4D-2FD3-4824-97BF-A4120F35162FQ40468052-763F41D1-6195-44BD-8A7E-A2D9D59AA7F4Q43264093-8D935CE8-BC81-44B2-8974-13E13F6841E3Q46105138-8D4FDF72-0E76-41DB-B5C3-DC5DDDD100B1Q46891599-50949D76-039D-4B7C-9809-28D8AAC6C7EEQ47206527-BFC40A89-8B6C-479A-A047-A8C6AAD71B05Q50491142-E46DF169-28CA-46B7-9B34-EA0B05930659Q52669996-3D46C710-369A-46E7-9C24-A4004449C14AQ53093550-CF570862-697D-4E14-B459-FD9EBCF870DFQ59607976-3D878867-9E43-4C80-BFA2-2B4C11EBFEBCQ62662387-12E87CA2-C023-40F3-89A3-69878B5C5D32Q71720549-0739121A-CD24-424E-BC9D-C9E3408D4BA9Q85849508-39B4E869-24D0-4FFB-A1B4-768EC4DB9465Q89573687-A999DA9C-C39E-4116-8822-071D08AEEE33Q91272239-BF12C078-44BA-4F04-BED1-AC6C729BE9C6Q91892637-184184FE-BDC2-4186-9CBC-D22CBB4A6EDAQ92652139-2D729123-5C77-49E8-9A87-6935514B2C0BQ92918905-4EBFE9E9-5DEE-416C-945B-E0A7E6F403C7
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicolas Lebegue
@ast
Nicolas Lebegue
@en
Nicolas Lebegue
@es
Nicolas Lebegue
@nl
type
label
Nicolas Lebegue
@ast
Nicolas Lebegue
@en
Nicolas Lebegue
@es
Nicolas Lebegue
@nl
prefLabel
Nicolas Lebegue
@ast
Nicolas Lebegue
@en
Nicolas Lebegue
@es
Nicolas Lebegue
@nl
P106
P1153
55924346400
P21
P31
P496
0000-0003-4245-2833